Treatment of aggressive lymphoma

Published: May 29, 2009
Abstract Views: 136
PDF: 175
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Treatment of aggressive B cell lymphomas is rapidly evolving with the introduction of monoclonal antibodies in association with chemotherapy. Reappraisal of the progress made with chemotherapy is important to decide which part of the past strategies with intensive treatment should still be used. Long term results of the first studies with R-CHOP, identify patients more likely to respond to treatment with Bcl2 over expression and low-intermediate risk factors. However, poor prognosis patients still exist and remain a challenge for investigations. Improving the use of chemotherapy and monoclonal antibodies will be the goals of the design of prospective studies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Gisselbrecht, C. (2009). Treatment of aggressive lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.275